| P2093 | author name string | Victor L Serebruany | |
| | Dan Atar | |
| | Stephen Ong | |
| | Alex Malinin | |
| P2860 | cites work | Inflammation and insulin resistance | Q22241893 |
| | Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 |
| | Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment | Q28185431 |
| | Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes | Q28192127 |
| | Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance | Q28194249 |
| | Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus | Q28194890 |
| | Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis | Q28217714 |
| | Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 |
| | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 |
| | Flow cytometric measurement of platelet function and reticulated platelets | Q33494785 |
| | A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group | Q34540010 |
| | Hypercoagulability in the metabolic syndrome. | Q36076184 |
| | Ex vivo analysis of T-cell function | Q36159944 |
| | Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes | Q36415843 |
| | The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 |
| | Rapid platelet-function assay: an automated and quantitative cartridge-based method | Q39486128 |
| | Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial | Q40363723 |
| | Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors | Q40864231 |
| | Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients | Q44122688 |
| | Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects | Q44523513 |
| | Cardiovascular disease risk stratification with stress single-photon emission computed tomography technetium-99m tetrofosmin imaging in patients with the metabolic syndrome and diabetes mellitus | Q44689148 |
| | Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity | Q44980053 |
| | Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial | Q45071179 |
| | Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers | Q45263399 |
| | Platelet and white blood cell counts are elevated in patients with the metabolic syndrome | Q46837959 |
| | Platelet adhesion in patients prone to arterial and venous thrombosis: the impact of gender, smoking and heredity. | Q50866111 |
| | Platelet activation in unstable coronary disease | Q68903080 |
| | RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 | Q69755626 |
| | New insights into the mechanisms of platelet adhesion and aggregation | Q72839781 |
| | PFA-100 system: a new method for assessment of platelet dysfunction | Q74525732 |
| | Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome | Q79753554 |
| | Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study) | Q83194465 |
| P433 | issue | 2 | |
| P921 | main subject | metabolic syndrome | Q657193 |
| | vascular disease | Q1266890 |
| P304 | page(s) | 207-213 | |
| P577 | publication date | 2007-05-26 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease | |
| P478 | volume | 25 | |